Several small-molecule inhibitors and monoclonal antibodies are now approved for the therapy of various cancers. Focusing on the example of the epidermal growth factor receptor inhibitors, this Review compares and contrasts these two classes of agents.
- Kohzoh Imai
- Akinori Takaoka